PURPOSE: Although ovarian cancer incidence rates have declined in the United States, less is known of ovarian cancer trends among survivors of breast cancer. Therefore, we examined second primary ovarian cancers after first primary breast cancer. METHODS: Data were obtained from the Surveillance, Epidemiology, and End Results program (1973 to 2008). Standardized incidence ratios (SIRs) were calculated as the observed numbers of ovarian cancers among survivors of breast cancer compared with the expected numbers in the general population. Absolute rates were measured as the incidence rates for second primary ovarian cancer by year of diagnosis of the first primary breast cancer adjusted for age of breast cancer diagnosis and years since diagnosis. RESULTS: SIRs for second primary ovarian cancer were elevated over the entire study period (SIR, 1.24; 95% CI, 1.2 to 1.3), whereas the absolute rates declined with an estimated annual percentage change near 1% (-1.34% to -0.09% per year). Secular trends for second ovarian cancers were similar after estrogen receptor (ER) -positive and ER-negative breast cancers, whereas the age-specific patterns varied significantly by ER expression (P for interaction < .001). The largest SIR was among women age less than 50 years with ER-negative breast cancer (SIR, 4.35; 95% CI, 3.5 to 5.4). CONCLUSION: Persistently elevated SIRs along with decreasing absolute rates over the entire study period suggest that ovarian cancers in both the general population and survivors of breast cancer are declining in parallel, possibly because of common risk factor exposures. Analytic studies are needed to further assess the parallel overall trends and the age-specific interaction by ER expression.
PURPOSE: Although ovarian cancer incidence rates have declined in the United States, less is known of ovarian cancer trends among survivors of breast cancer. Therefore, we examined second primary ovarian cancers after first primary breast cancer. METHODS: Data were obtained from the Surveillance, Epidemiology, and End Results program (1973 to 2008). Standardized incidence ratios (SIRs) were calculated as the observed numbers of ovarian cancers among survivors of breast cancer compared with the expected numbers in the general population. Absolute rates were measured as the incidence rates for second primary ovarian cancer by year of diagnosis of the first primary breast cancer adjusted for age of breast cancer diagnosis and years since diagnosis. RESULTS: SIRs for second primary ovarian cancer were elevated over the entire study period (SIR, 1.24; 95% CI, 1.2 to 1.3), whereas the absolute rates declined with an estimated annual percentage change near 1% (-1.34% to -0.09% per year). Secular trends for second ovarian cancers were similar after estrogen receptor (ER) -positive and ER-negative breast cancers, whereas the age-specific patterns varied significantly by ER expression (P for interaction < .001). The largest SIR was among women age less than 50 years with ER-negative breast cancer (SIR, 4.35; 95% CI, 3.5 to 5.4). CONCLUSION: Persistently elevated SIRs along with decreasing absolute rates over the entire study period suggest that ovarian cancers in both the general population and survivors of breast cancer are declining in parallel, possibly because of common risk factor exposures. Analytic studies are needed to further assess the parallel overall trends and the age-specific interaction by ER expression.
Authors: William D Foulkes; Kelly Metcalfe; Ping Sun; Wedad M Hanna; Henry T Lynch; Parviz Ghadirian; Nadine Tung; Olufunmilayo I Olopade; Barbara L Weber; Jane McLennan; Ivo A Olivotto; Louis R Bégin; Steven A Narod Journal: Clin Cancer Res Date: 2004-03-15 Impact factor: 12.531
Authors: R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard Journal: Lancet Date: 2011-12-05 Impact factor: 79.321
Authors: Jieqiong Liu; Wen Jiang; Kai Mao; Yi An; Fengxi Su; Betty Y S Kim; Qiang Liu; Lisa K Jacobs Journal: Breast Cancer Res Treat Date: 2015-03-13 Impact factor: 4.872
Authors: Gabriella Ferrandina; Giulia Amadio; Andrea Marcellusi; Elena Azzolini; Anna Puggina; Roberta Pastorino; Walter Ricciardi; Giovanni Scambia Journal: Clin Drug Investig Date: 2017-11 Impact factor: 2.859
Authors: Koji Matsuo; Rachel S Mandelbaum; Hiroko Machida; Kosuke Yoshihara; Shinya Matsuzaki; Maximilian Klar; Franco M Muggia; Lynda D Roman; Jason D Wright Journal: Arch Gynecol Obstet Date: 2020-03-23 Impact factor: 2.344
Authors: Nicole Urban; Sarah Hawley; Holly Janes; Beth Y Karlan; Christine D Berg; Charles W Drescher; JoAnn E Manson; Melanie R Palomares; Mary B Daly; Jean Wactawski-Wende; Mary J O'Sullivan; Jason Thorpe; Randal D Robinson; Dorothy Lane; Christopher I Li; Garnet L Anderson Journal: Gynecol Oncol Date: 2015-09-03 Impact factor: 5.482
Authors: Chloe J Bright; Raoul C Reulen; David L Winter; Daniel P Stark; Martin G McCabe; Angela B Edgar; Clare Frobisher; Michael M Hawkins Journal: Lancet Oncol Date: 2019-02-21 Impact factor: 41.316